Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.
The firm saw total revenues decrease 7 percent, with core revenues down 4 percent and base business core revenue growth of 6 percent.
The firm's planned launches include a respiratory virus panel, a gastrointestinal panel, and a fingerstick tuberculosis test, it revelaed this week at ECCMID.
BioMérieux, Biocartis, Beckman Coulter Gain FDA 510(k) Clearances in February
BioFire Diagnostics' Spotfire Respiratory Panel detects several viruses including SARS-CoV-2, adenomvirus, and the flu.
Boston University, Cepheid Get FDA EUAs for COVID-19, Monkeypox Tests
The Cepheid test qualitatively detects DNA from monkeypox virus clade II and non-variola Orthopoxvirus in human lesion swab specimens.
Dec 30, 2022
Top 10 Articles on 360Dx in 2022
Nov 7, 2022
Cepheid Nabs CE Mark for Group B Strep Test
Jul 25, 2022
Apr 25, 2022
Jan 27, 2022
Danaher Q4 Revenues Rise 21 Percent
Oct 21, 2021